Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.54 +2.62 (+8.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation. 
Via Benzinga
News headline image
Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play ↗
Canaccord said Viking’s obesity pipeline is worth far more than the current valuation. 
Via Stocktwits
‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗
Via Stocktwits
News headline image
AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today ↗
Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61. 
Via Benzinga
Topics Stocks
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗
Via Stocktwits
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera ↗
Via Stocktwits
News headline image
2 Monster Stocks in the Making ↗
There might still be time to get in on the ground floor. 
Via The Motley Fool
News headline image
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗
Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks. 
Via Stocktwits
News headline image
Is There a Future for Viking Therapeutics? ↗
The weight loss drug company was counted out far too early in the summer, but investors are warming to it again. 
Via The Motley Fool
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
News headline image
Earnings Preview For Viking Therapeutics ↗
 
Via Benzinga
News headline image
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗
Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross. 
Via Benzinga
News headline image
Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils ↗
Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria. 
Via Benzinga
News headline image
Here's Why Shares in Viking Therapeutics Shot Higher in October ↗
Three factors took Viking's shares higher in the month. 
Via The Motley Fool
News headline image
Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets. ↗
It's a great idea to watch the latest moves of this expert investor. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Prediction: The Next Eli Lilly Might Already Be Trading Under $50 ↗
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left. 
Via The Motley Fool
News headline image
Should You Buy Viking Therapeutics Before Nov. 5? ↗
Viking's stock surged in one trading session after a positive clinical trial report last year. 
Via The Motley Fool
News headline image
3 Promising Growth Stocks That Are Down Around 60% From Their Highs ↗
These stocks may be down as of late, but investors shouldn't count them out in the long run. 
Via The Motley Fool
News headline image
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise ↗
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Viking Therapeutics: High Risk, High Reward Play ↗
Via MarketBeat
News headline image
Here's Why This Obesity Drug Company's Share Price Soared Today ↗
The company had positive updates on its clinical trials. 
Via The Motley Fool
Topics Earnings
News headline image
Why Is Viking Therapeutics Stock Rising Today? ↗
Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials. 
Via Benzinga
News headline image
Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside ↗
Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies ↗
Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests. 
Via Investor's Business Daily
News headline image
Viking Therapeutics (NASDAQ:VKTX) Reports Q3 2025 Earnings Miss and 2.8% After-Hours Decline ↗
Viking Therapeutics Q3 2025 results show an earnings miss, with shares falling. The company's key Phase 3 obesity trial remains on track. 
Via Chartmill
Topics Earnings
News headline image
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck. 
Via Benzinga
News headline image
Earnings Scheduled For October 22, 2025 ↗
 
Via Benzinga
News headline image
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond ↗
These companies are jockeying for position in a potential $150 billion market opportunity. 
Via The Motley Fool
News headline image
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? ↗
These stocks have climbed in the triple digits over the past few years. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.